資源描述：
《治療乙型肝炎新藥肝龍膠囊的藥效學(xué)初步研究【精品論文】.doc》由會員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫。
1、治療乙型肝炎新藥肝龍膠囊的藥效學(xué)初步研究作者：小小小作者：杜一民，陳鴻珊，李樹楠，李壯，李小兵，張華明，方春生【關(guān)鍵詞】肝龍膠囊；,,鴨乙型肝炎病毒；,,鴨乙肝動物模型；,,實(shí)驗(yàn)性肝損傷；，，美洲大嫌摘要：n的觀察肝龍膠囊對鴨乙型肝炎病毒的抑制效果和對實(shí)驗(yàn)性肝損傷的保護(hù)作用。方法(1)以鴨乙型肝炎病毒(DHBV)靜脈注射感染雛鴨為模型，于感染第7天后分組灌胃肝龍(GL)膠囊浸膏0.5,1.5,3.0g?kgl?dl,陽性對照組給予無環(huán)鳥昔(ACV)或磷竣基甲酸鈉(PFA)o采用斑點(diǎn)雜交方法檢測鴨血清DHBVDNA,以病毒抑制率為療效指標(biāo)；(2)以昆明種小鼠腹腔注射CC14肝損傷為模型，給予
2、GL浸膏(200mg-kgl)o測定SGPT值，并取肝臟作病理形態(tài)學(xué)觀察。結(jié)果(1)GL三個不同劑量紐對DHBV均有不同程度的抑制作用，有一定的量效關(guān)系；(2)GL降低CC14肝損傷小鼠血清SGPT值并減輕肝細(xì)胞損傷。結(jié)論肝龍膠囊可抑制雛鴨體內(nèi)DHBVDXA的復(fù)制并能保護(hù)CC14所致的小鼠肝損傷。關(guān)鍵詞：肝龍膠囊；鴨乙型肝炎病毒；鴨乙肝動物模型；實(shí)驗(yàn)性肝損傷；美洲大燥TheHepaticPharmacologicalEffectsofGanlongCapsulesinvivo.Abstract：ObjectiveToobservetheantiviralactivityofGanlongC
3、apsuleagainstduckHepatitisBvirus(DHBV)anditsprotectiveeffectsonexperimentalliverinjuryinvivo.Methods(1)ExperimentalresearchesonantiviralactivityofGanlongCapsulesagainstduckhepatitisBvirus:TheduckliepatitisBmodelwasmadebyinjectingDHBVintotheveinsofone-day-oldBeijingduckontheseventhdayafterinfectedb
4、yDHBV,GanlongCapsulewasgivenbyintragastricadministrationfor10daystogroupI(0.5g■kgl■dl),groupII(1.5g■kgl■dl),groupIII(3.0g?kgl?dl),bidX10d,anddetectedthelevelsofDHBV-DNAintheduckbloodseraobtainedseparatelyonthedaybeforegivingGanlongCapsule,thefifthdayandtenthdayaftergivingGanlongCapsule,andthethird
5、dayafterwithdrawingGanlongCapsule,byserumdotblothybridization.Thetrialwascomparedwithacyclovor(ACV)orphosphonoformate(PFA).(2)ProtectiveeffectsofGanlongcapsuleonexperimentailiverinjuryinmice:Acutehepaticinjurywasinducedbyintraperitonealinjectionof0.2%CC1410ml■kgl,Ganlong(200mg?kgl)wasgivenbyintrag
6、astricorintraperitonealadministrationfor2days,bid.TheserumSGPTwereexaminedandthehistopathologicalchangesofhepatictissuewasmeasured.Results(1)TheresultsofthreeexperimentsshowedthatthelevelsofseraDHBVDNAdecreasedinthetreatmentgroupsofGanlong,andinadose-effectmanner.ThegroupIII(3.0g■kgl?dl)inhibited(
7、P<0.01)theserumDHBVDNAsignificantly,andafterstoppingthetreatmentfor6days,serumDHBV-DNAleveldidnotreturnsignificantly,andtheinhibiteffectswerenodifferent,comparedwiththetreatmentgroupofphosphonoformate(PFA)oracycl
